Inspirion Wealth Advisors LLC Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Inspirion Wealth Advisors LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 13.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 599 shares of the company’s stock after buying an additional 71 shares during the quarter. Inspirion Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $531,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Capital Planning LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth $262,000. CHURCHILL MANAGEMENT Corp purchased a new stake in Eli Lilly and Company during the first quarter worth approximately $6,916,000. M&G Plc acquired a new position in Eli Lilly and Company in the first quarter valued at approximately $8,896,000. HighPoint Advisor Group LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $9,878,000. Finally, Leo Wealth LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $3,355,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Berenberg Bank lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Barclays lifted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Guggenheim raised their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Finally, BMO Capital Markets lifted their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $1.61 during mid-day trading on Friday, reaching $887.16. The company had a trading volume of 1,971,436 shares, compared to its average volume of 3,031,093. The stock’s 50-day simple moving average is $900.13 and its 200-day simple moving average is $847.35. The company has a market capitalization of $843.16 billion, a P/E ratio of 130.66, a P/E/G ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 1 year low of $531.61 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. On average, equities analysts predict that Eli Lilly and Company will post 16.49 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.